JournalScan
| The first 150 words of the full text of this article appear below. |
HEART FAILURE
Endothelins are powerful vasoconstrictive peptides that have been shown to correlate with a poor prognosis in patients with heart failure. Therefore could tezosentan, an intravenous short-acting endothelin receptor antagonist, improve outcomes in patients with acute heart failure?
Two identical, concurrent trials named VERITAS (Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies) were conducted over three continents and enrolled 1435 patients. All participants had been admitted within the previous 24 hours with acute decompensated heart failure that did not respond to diuretics, and went on to receive either placebo or IV tezosentan for 24–72 hours. The coprimary endpoints were change in dyspnoea (measured using a visual analogue scale at 3, 6, and 24 hours) and incidence of death or worsening heart failure at 7 days in both trials.
Baseline dyspnoea scores were similar in the two treatment groups, and the mean left ventricular ejection fraction (where measured)
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
